Bellerophon Therapeutics has completed enrollment of its 80-patient Phase 2 clinical trial of INOpulse for the treatment of pulmonary arterial hypertension (PAH). PAH is a life-threatening, progressive disorder characterized by abnormal constriction of the arteries of the lung, leading to increased blood pressure in the lungs and abnormal strain on the heart's right ventricle, eventually leading to heart failure.
PAH occurs when most of the very small arteries throughout the lungs narrow in diameter, increasing the resistance to blood flow through the lungs. To overcome the increased resistance, pressure increases in the pulmonary artery and the right ventricle -- the heart chamber that pumps blood into the pulmonary artery. In addition, PAH may cause changes to the blood vessel lining that hinders the natural production of nitric oxide.
Prior to the availability of current treatments, primary PAH patients had an average survival of less than three years. There are a number of drugs approved for the treatment of PAH that work by reducing vascular resistance. However, despite the availability of multiple therapies for this indication, the mortality rate for PAH patients remains high, with estimates of median survival ranging from three to five years.
Bellerophon's INOpulse device delivers brief, controlled pulses of nitric oxide, which is a selective, short-acting pulmonary vasodilator, that are inhaled by the patient. INOpulse is portable, allowing for treatment of ambulatory patients on daily basis outside the hospital. Nitric Oxide is naturally produced and released by portions of the blood vessels and results in smooth muscle relaxation. In particular, nitric oxide controls muscle tone in blood vessels and thus is an important factor in regulating blood pressure. As the muscles of the blood vessels relax, blood flow increases, helping the heart to deliver more blood to the body.
This Phase 2 study, being conducted at 52 sites in the United States and Canada, is a randomized, placebo-controlled trial of INOpulse as an add-on therapy for use in patients whose disease is progressing despite treatment with other PAH medications. The trial will determine the safety, tolerability and efficacy in this population of two different doses of INOpulse for PAH. The primary endpoint is a change in pulmonary vascular resistance at 16 weeks from baseline. Secondary endpoints include change in mean pulmonary arterial pressure and cardiac index as well as change in six-minute walk distance. The trial is expected to be completed by the end of 2014.
"The U.S. Food and Drug Administration has granted orphan drug designation for nitric oxide for the treatment of PAH, which will give us seven years of exclusivity in the U.S. if INOpulse is the first inhaled nitric oxide therapy approved in this indication," stated Daniel Tasse, interim chief executive officer of Bellerophon. "There is presently no cure for PAH and, despite several approved therapies, the mortality rate remains high. The completion of enrollment in this important Phase 2 trial is therefore a key milestone for Bellerophon, and we look forward to the continued development of this potential new first-in-class therapy."
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- What Do EU Countries Give Up When They Opt-out Of GMO Crops? And For Whom?
- Coincidence Or Conspiracy? Investigating If Believers Really See So Much Secret Design
- Nobel Prize Validates Chinese Medicine? Nope.
- An Easy Problem
- Sex Change Hormonal Treatments Alter Brain Chemistry
- Houston Is A Lot More Tolerant Of Immigrants Than Copenhagen Is
- Prenatal BPA Exposures (Don’t) Affect Birth Weight
- "This is a bit of irony: Mother Jones, which can never be bothered with facts or truth and got sued..."
- "Great piece Steve. While the potential for suffering and death in Africa especially thanks to this..."
- "I look forward to more threats and libel from you in the very near future. It's your stock in trade..."
- "Dear Mr. Campbell: Again you spin and dissemble. It was quite clear from the many tweets between..."
- "One of us does not know what libel means (hint: It is you). Calling me a felon and a fraud is libel..."
- FDA-Approved Test for Meningitis is a Home Run
- Trends In Smoking – Chinese Men In Peril, American Women Get Better Cessation
- Counter-Point: Activists Operate By Outrage, Not Fear
- Whole Foods Recalls Organic Roquefort Cheeses After Listeria Found
- Suicide Tries Linked to Weight-Loss Surgery? Study Doesn’t Show
- Following Rules, Refreezing Thawed Meat is Safe
- Beetles provide clues about the genetic foundations of parenthood
- Teens value results of genetic tests to inform future life decisions
- Trees to power: McMaster engineers build better energy storage device
- High dose chemo & stem cell transplantation results in long-term survival for amyloid patients
- 'Blind analysis' could reduce bias in social sciences papers